Jonathan C. Javitt - 09 Apr 2025 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Chairman and Chief Scientist, Director, 10%+ Owner
Issuer ticker: NRXP
Reported as of: 09 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Sep 2025, 15:36:07 UTC
Prior SEC filing: 18 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Javitt

Key filing fact

Jonathan C. Javitt filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 10 Sep 2025.

Key facts

This page summarizes Jonathan C. Javitt's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2025, 15:36.

Change

Previous filing in this sequence was filed on 18 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001303782 Primary reporting owner

Javitt Jonathan C

Relationship: Chairman and Chief Scientist, Director, 10%+ Owner
Address: C/O NRX PHARMACEUTICALS, INC., 1201 ORANGE STREET, SUITE 600, WILMINGTON
Signature: /s/ Jonathan Javitt
Signature date: 10 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRXP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +125,000
Change %
Price: $0.000000
Shares after: 125,000
Date: 09 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $1.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued